Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

In 2008 the results of a small study were published reporting on the use of choline stabilized orthosilicic acid a form of silicon, or placebo in 184 women with low […]

PARATHYROID HORMONE (PTH) A new class of osteoporosis treatments called bone formation agents Parathyroid hormone analogues belong to a class of osteoporosis medications which can promote bone growth. In Canada, […]

SAC Members and Research MD, MSC, FRCPC KristinClemens Dr. Kristin Clemens is a Clinician-Researcher in the Departments of Medicine and Epidemiology and Biostatistics at Western University. She is also the […]

Donate Today Your gift will immediately help to educate, empower, and support individuals and communities on bone health and in the risk-reduction and treatment of osteoporosis. Donate Cook With OC […]

MEET THE CMC FACULTY Dr. Cathy Craven University of Toronto  Toronto, ON Cathy Craven is the Toronto Rehabilitation Institute/ University of Toronto Chair in Spinal Cord Injury (SCI) Rehabilitation, Professor […]

Board of Directors Jeannette Briggs Chair | Oakville, ON Jeannette has more than 25 years of experience working in the energy sector.  She has held a wide-range of jobs within […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada – Updated August 6, 2013 Calcitonin is a hormone found naturally in our bodies. A synthetic form […]